BAG1 down‐regulation increases chemo‐sensitivity of acute lymphoblastic leukaemia cells
Abstract BCL2‐associated athanogene‐1 (BAG1) is a multi‐functional protein that is found deregulated in several solid cancers and in paediatric acute myeloid leukaemia. The investigation of BAG1 isoforms expression and intracellular localization in B‐cell acute lymphoblastic leukaemia (B‐ALL) patient‐derived specimens revealed that BAG1 levels decrease during disease remission, compared to diagnosis, but drastically increase at relapse. In particular, at diagnosis both BAG1‐L and BAG1‐M isoforms are mainly nuclear, while during remission the localization pattern changes, having BAG1‐M almost exclusively in the cytosol indicating its potential cytoprotective role in B‐ALL. In addition, knockdown of BAG1/BAG3 induces cell apoptosis and G1‐phase cell cycle arrest and, more intriguingly, shapes cell response to chemotherapy. BAG1‐depleted cells show an increased sensitivity to the common chemotherapeutic agents, dexamethasone or daunorubicin, and to the BCL2 inhibitor ABT‐737. Moreover, the BAG1 inhibitor Thio‐2 induces a cytotoxic effect on RS4;11 cells both in vitro and in a zebrafish xenograft model and strongly synergizes with pan‐BCL inhibitors. Collectively, these data sustain BAG1 deregulation as a critical event in assuring survival advantage to B‐ALL cells..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Journal of Cellular and Molecular Medicine - 25(2021), 18, Seite 9060-9065 |
| Beteiligte Personen: |
Mariotto, Elena [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine |
|---|
| Umfang: |
6 |
|---|
| doi: |
10.1111/jcmm.16822 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY008017255 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY008017255 | ||
| 003 | DE-627 | ||
| 005 | 20230307173952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230216s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/jcmm.16822 |2 doi | |
| 028 | 5 | 2 | |a JCMM_JCMM16822.xml |
| 035 | |a (DE-627)WLY008017255 | ||
| 035 | |a (WILEY)JCMM16822 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.46 |2 bkl | ||
| 100 | 1 | |a Mariotto, Elena |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BAG1 down‐regulation increases chemo‐sensitivity of acute lymphoblastic leukaemia cells |
| 264 | 1 | |c 2021 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine | ||
| 520 | |a Abstract BCL2‐associated athanogene‐1 (BAG1) is a multi‐functional protein that is found deregulated in several solid cancers and in paediatric acute myeloid leukaemia. The investigation of BAG1 isoforms expression and intracellular localization in B‐cell acute lymphoblastic leukaemia (B‐ALL) patient‐derived specimens revealed that BAG1 levels decrease during disease remission, compared to diagnosis, but drastically increase at relapse. In particular, at diagnosis both BAG1‐L and BAG1‐M isoforms are mainly nuclear, while during remission the localization pattern changes, having BAG1‐M almost exclusively in the cytosol indicating its potential cytoprotective role in B‐ALL. In addition, knockdown of BAG1/BAG3 induces cell apoptosis and G1‐phase cell cycle arrest and, more intriguingly, shapes cell response to chemotherapy. BAG1‐depleted cells show an increased sensitivity to the common chemotherapeutic agents, dexamethasone or daunorubicin, and to the BCL2 inhibitor ABT‐737. Moreover, the BAG1 inhibitor Thio‐2 induces a cytotoxic effect on RS4;11 cells both in vitro and in a zebrafish xenograft model and strongly synergizes with pan‐BCL inhibitors. Collectively, these data sustain BAG1 deregulation as a critical event in assuring survival advantage to B‐ALL cells. | ||
| 700 | 1 | |a Corallo, Diana |4 aut | |
| 700 | 1 | |a Pantile, Marcella |4 aut | |
| 700 | 1 | |a Giarin, Emanuela |4 aut | |
| 700 | 1 | |a Pigazzi, Martina |4 aut | |
| 700 | 1 | |a Basso, Giuseppe |4 aut | |
| 700 | 1 | |a Viola, Giampietro |4 aut | |
| 700 | 1 | |a Aveic, Sanja |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Cellular and Molecular Medicine |g 25(2021), 18, Seite 9060-9065 |w (DE-627)WLY007997361 |x 15824934 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2021 |g number:18 |g pages:9060-9065 |g extent:6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.46 |q ASE |
| 951 | |a AR | ||
| 952 | |d 25 |j 2021 |e 18 |h 9060-9065 |g 6 | ||